Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have shown that transferrin-gallium (Tf-Ga) blocks DNA synthesis through inhibition of cellular iron incorporation and a diminution in the activity of the iron-dependent M2 subunit of ribonucleotide reductase. To examine the mechanisms of drug resistance to gallium, we developed a subline of HL60 cells (R cells) which is 29-fold more resistant to growth inhibition by gallium nitrate than the parent line (S cells). R cells displayed a 2.5-fold increase in transferrin (Tf) receptor expression, without a change in receptor affinity for Tf. The uptake and release of 67Ga were similar for both S and R cells. The uptake of 59Fe-Tf by S cells was inhibited by gallium nitrate over 24-48 h of incubation. In contrast, 59Fe-Tf uptake by R cells, although initially inhibited by gallium nitrate at 24 h, was no longer inhibited at 48 h of incubation. 59FeCl3 uptake by R cells was significantly greater than that of S cells, regardless of the time in culture. Despite the increase in 59Fe uptake by R cells, the ferritin content of these cells was lower than that of S cells. The ribonucleotide reductase electron spin resonance signal of R cells was comparable to that of S cells. R cells were not cross-resistant to Adriamycin, vincristine, cis-platinum or hydroxyurea. Resistance to gallium nitrate in this subline of HL60 cells results primarily from the ability of cells to overcome the gallium-induced block in iron incorporation. In addition, intracellular iron in R cells appears to traffic preferentially to a non-ferritin compartment.
Cancer Res 1990 Aug 01
PMID:Development of drug resistance to gallium nitrate through modulation of cellular iron uptake. 216 39

Blood serum levels of ferritin and trophoblastic globulin were measured by immunoassay in 389 and 114 cases, respectively, suffering malignant or benign tumors of the uterus and ovary as well as in controls. Hyperferritinemia identified at serum ferritin levels in excess of 200 micrograms/l was established in 94% of cases of ovarian cancer, 57%--benign ovarian tumors, 60%--endometrial carcinoma and in 16% of patients with uterine myoma. Patients with ovarian and uterine malignancies were shown to have the highest serum ferritin levels. The study failed to establish an increase in trophoblastic globulin concentration in cases of nontrophoblastic tumors of the genitals. It is suggested that serum ferritin level be measured in patients presenting with ovarian and uterine tumors and in subjects at high risk for ovarian cancer to assure early diagnosis of disease.
 ...
PMID:[Serum ferritin and trophoblastic globulin in genital tumors in women]. 218 Feb 8

This clinical trial was performed to study the effects of intravenously (IV) administered recombinant human (rh) erythropoietin (EPO) at escalating doses (150, 300, and 450 U/kg, administered as an IV bolus injection, twice weekly, for 6, 4, and 4 weeks, respectively) in five patients with low-grade non-Hodgkin's lymphoma (Ig NHL) and bone marrow involvement and one patient with multiple myeloma (MM). All patients were anemic due to underlying disease. None of the patients had a history of bleeding, hemolysis, renal insufficiency, or other disorders causing anemia in addition to bone marrow infiltrating malignancy. Endogenous EPO serum levels were significantly increased in all patients (74 to 202 mU/mL). Five patients (one MM, four small-cell lymphocytic [SCLC] NHL) showed a dramatic increase of hemoglobin (Hb), hematocrit (Hk) and RBC count becoming obvious on the second EPO dose level. Initial ferritin serum values, which were high mostly due to polytransfusion, were significantly reduced in responding patients. Erythropoiesis of one patient with extensive follicular mixed (fm) NHL did not respond to EPO treatment. Platelet (PLT) count increase (greater than 75% above starting levels) during and following EPO therapy was observed in one patient with MM. Adverse events due to EPO therapy have not been recorded. These findings point out a previously unrecognized capacity of EPO given at pharmacologic doses to stimulate erythropoiesis in patients with anemia due to bone marrow infiltration by neoplastic lymphocytes in spite of enhanced endogenous EPO expression.
 ...
PMID:Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. 218 57

We have used the monoclonal antibodies 2A4 (specific for the H subunit of human ferritin) and LO3 (specific for the L subunit) for immunocytochemical detection of ferritin in bone marrow and peripheral blood cells from normal subjects and patients with various haematological disorders. Formalin-fixed slides were stained by the immunoalkaline phosphatase procedure (APAAP). In normal subjects, ferritin could be found only in bone marrow smears and appeared to be largely confined to erythroid precursors and reticuloendothelial cells. The more immature erythroid precursors contained higher concentrations of cellular ferritin. Although evaluation could be only semiquantitative, erythroblast ferritin appeared to be more reactive with the monoclonal 2A4 (15 +/- 7% positive erythroblasts) than with the monoclonal LO3 (6 +/- 5% positive erythroblasts), indicating that H-type ferritin was predominant, particularly in proerythroblasts and basophilic erythroblasts. By contrast, the ferritin present in reticuloendothelial cells appeared to be predominantly of L-type. Patients with iron deficiency showed low levels of positive erythroblast, whereas the reverse was true in patients with transfusional iron overload. Intense positivity for reticuloendothelial cell ferritin was found in patients with anaemia of chronic disease. In myelodysplastic syndromes and acute myeloid leukaemia (AML), ferritin positivity was generally very strong at any stage of erythroblast development, particularly with the monoclonal antibody 2A4. Perls-positive perinuclear granules of ring sideroblasts were not stained, confirming that mitochondrial iron deposition is not in the form of ferritin. In AML and myelodysplastic syndromes with excess of blasts, ferritin could be detected also in immature myeloid cells. These data indicate that: (a) in normal conditions ferritin is mainly expressed in red cell precursors and reticuloendothelial cells, and this is in keeping with the peculiar role of these cells in iron metabolism; (b) abnormal cell ferritin contents can be observed in both iron overload and malignancy.
 ...
PMID:Immunocytochemical detection of ferritin in human bone marrow and peripheral blood cells using monoclonal antibodies specific for the H and L subunit. 226 53

Histopathologic features of 18 cases of composite ganglioneuroblastoma (CGNB) were studied with immunohistochemical staining techniques using antibodies against S-100 protein (S-100), ferritin (FER), and leukocytic common antigen (LCA). Cases of CGNB were divided on the basis of the morphologic features of neuroblastic elements into three prognostic subgroups: "Type A Intermixed," having individual microscopic nests of neuroblasts (N = 4, 100% survival); "Type B Intermixed," having microscopic aggregates of multiple neuroblastic nests (N = 6, 67% survival); and "Nodular," having grossly visible nodule(s) of neuroblastic proliferation (N = 8, 0% survival). Survival rates are significantly different for the prognostic subgroups (P less than 0.025). Each prognostic subgroup demonstrated an immunohistochemically distinct pattern of stromal cell composition in the neuroblastic elements: Type A Intermixed had numerous S-100 cells and no FER cells, Type B Intermixed contained many S-100 cells and a moderate number of FER cells, and Nodular had few S-100 cells with many FER cells. The S-100 and FER scores, determined by counting the positive cells through a line sampling method, differed significantly between these prognostic subgroups. Lymphocytic aggregations in tumor tissue evaluated by volumetric assessment with LCA staining, on the other hand, showed no contribution in predicting the outcome of the patients. There was also an inverse relationship between S-100 and FER score, suggesting a relationship between the relative predominance of these stromal cell types, tumor histopathologic features, and the biologic behavior of CGNB.
Cancer 1990 Jan 15
PMID:Histopathologic features of composite ganglioneuroblastoma. Immunohistochemical distinction of the stromal component is related to prognosis. 229 48

When 111In-labeled murine monoclonal antibodies are used in radio-scintigraphic diagnostic procedures, a large fraction of the injected radionuclide is sequestered by the liver. Neither the cells responsible for the uptake nor the mechanism of uptake are known. Little is known about either the site within the liver of antibody metabolism or the form of the products of metabolism. In these studies, the uptake and metabolism of a monoclonal antibody, B6.2 radiolabeled with 111In or 125I [either intact B6.2 or F(ab')2] were determined in rats. One h after injection of either 125I- or 111In-diethylenetriaminepentaacetic acid (111In-DTPA)-labeled B6.2, the predominant liver cell in which the radionuclide was found was the parenchymal cell. At this time, the absolute uptake of 125I in the liver was 0.23 +/- 0.06% (SD) of the injected dose compared to 0.61 +/- 0.06% when the radionuclide was 111In. Removal of the Fc portion of the antibody reduced the absolute liver uptake of 125I to 0.10 +/- 0.01 and the absolute uptake of 111In to 0.16 +/- 0.06. Both radionuclides were still associated predominantly with the parenchymal cell. Using size exclusion high performance liquid chromatography analysis of liver supernatants the metabolism of radiolabeled B6.2 was followed for 24 h. Of the radioactivity recovered, 47.9% of the 125I was precipitable by centrifugation (and presumed bound to cell membranes) while 15.4% was attached to B6.2 found in the cytosol. In contrast, when 111In-DTPA-B6.2 was administered, 16.0% of 111In recovered from the liver was precipitable by centrifugation, and 6.5% was attached to B6.2 found in the cytosol. Sixty % of the 111In was recovered as a low molecular weight (less than 1000) component in the cytosol. This metabolite was not immunoreactive, nor did it comigrate with ferritin, and was resolved into four components by ion exchange high performance liquid chromatography. Of these, only a minor component cochromatographed with an 111In-DTPA standard. These data suggest that the large accretion of radionuclide by the liver is due to uptake of monoclonal antibodies by an Fc receptor-mediated mechanism and the subsequent accumulation of low molecular weight metabolites, presumably 111In-DTPA, attached to one or more amino acids. The reasons for the entrapment of metabolites in the liver are under investigation.
Cancer Res 1990 Feb 01
PMID:Uptake and metabolism of 111In-labeled monoclonal antibody B6.2 by the rat liver. 229 33

Out of 104 patients with microcytosis (MCV less than 80 fl), 69% had an iron deficiency, 21% a chronic disease and 10% hemoglobinopathy or thalassemia trait. The absence of bone marrow iron stores or the response to iron supplementation were used to establish the diagnosis iron deficiency. On the basis of sensitivity (90%) and specificity (100%), the serum ferritin concentration is more suitable for assessment of iron deficiency than the serum iron concentration, the total iron-binding capacity or the percentual saturation of transferrin. The red cell distribution width (RDW) is the parameter with the highest sensitivity for iron deficiency (94%). An RDW value within the reference interval can be used to exclude iron deficiency in those cases in which the serum ferritin concentration does not accurately reflect the iron stores owing to severe tissue damage, as in inflammation or malignancy.
 ...
PMID:Evaluation of microcytosis using serum ferritin and red blood cell distribution width. 231 92

There is little data available on the use of erythropoietin in CAPD patients. The available pharmacokinetic and clinical data suggest that a low dose of subcutaneous erythropoietin might be effective. Seven CAPD patients, without active malignancy or infection, self-administered erythropoietin, 2,000 units (a mean of 32 units/kg) subcutaneously, three times a week. The Hct rose from 23% to 31% in a mean treatment time of 7 weeks, or a rate of rise of 1.2% per week. Three of the patients had previously been transfusion dependent. One of these patients and two additional had iron overload (ferritin level greater than 2,000 ng/ml). The drug was paid for by Medicaid (two patients) or private insurance, with the patient paying the uncovered portion, generally 20%. Side effects were minimal. Low dose subcutaneous erythropoietin is effective in CAPD patients.
 ...
PMID:The use of subcutaneous erythropoietin in CAPD patients. 235 Sep 7

The relationship of iron-binding proteins to prognosis was studied in 50 children at the Children's Hospital of Philadelphia, newly diagnosed with Hodgkin's disease (HD). There were five patients with Stage I, 18 with Stage II, 14 with Stage III, and 13 with Stage IV. Initial serum ferritin, transferrin, iron, hemoglobin (Hb), erythrocyte sedimentation rate (ESR), and A or B symptoms were analyzed for their association with progression-free survival (PFS). There was a linear increase of mean and median ferritin levels and a decrease of mean and median transferrin levels with advancing stages. Also, there was a significant inverse correlation between ferritin and transferrin (P less than 0.001). In univariate analyses, high ferritin (greater than 142 ng/ml) (P = 0.02) and low transferrin (less than or equal to 250 mg/dl) (P = 0.008) were significantly associated with poor PFS. Serum iron, Hb, ESR, and A or B symptoms were not associated with PFS. Stepwise proportional hazards regression analysis of all factors showed that transferrin was the only factor significantly associated with PFS. These preliminary results suggest that serum transferrin can also be used as a prognostic factor in addition to serum ferritin and that it may be helpful to assay both serum ferritin and transferrin as prognostic factors in childhood HD. Further testing of large groups of patients is needed to determine whether they are independent of tumor bulk and other established prognostic factors.
Cancer 1990 Jul 15
PMID:Prognostic importance of serum transferrin and ferritin in childhood Hodgkin's disease. 236 13

Tumour markers are substances that occur at elevated blood levels in patients with certain tumours. When their specificity and sensitivity are known, markers can be used to monitor cancer patients. No single marker is specific and sensitive for a certain tumour, so a tumour-marker combination is used. The efficacy of CA 125, ferritin, TPA and CEA was demonstrated in 162 ovarian cancer patients. With the same combination, we found a statistically significant 91.7% correlation between the clinical course of the disease and the marker profile in 60 further patients. Tumour markers can also help make a prognosis. In 34 patients the marker profile accurately predicated the findings at second-look surgery. Thus, biochemical monitoring may supplant the second-look procedure. 68 patients were followed for a mean of 2.7 years after completion of chemotherapy. In 95.6% the tumour-marker analysis correlated with the clinical and radiologic course. This means that the end of chemotherapy depends on biochemical monitoring, and second-line therapy can be initiated sooner.
 ...
PMID:[Tumor marker combination versus second-look operation in ovarian cancer]. 237 87


<< Previous 1 2 3 4 5 6 7 8 9 10